In re Insulin Pricing Litigation
Jan, 2025
In re Insulin Pricing Litigation (D.N.J.)
Plaintiffs in this antitrust litigation allege that drug manufacturers colluded with pharmacy business managers (“PBMs”) to artificially and fraudulently inflate the price of analog insulin drugs in the United States. NastLaw is co-lead counsel for a proposed class of direct purchasers, and a member of the Plaintiffs’ Steering Committee for a proposed class of third-party payors. The litigation is currently in the discovery stage.